ESOPJun 4, 2026, 04:24 PM
OnKure Therapeutics Stockholders Approve Amended Equity Incentive Plan
AI Summary
OnKure Therapeutics' stockholders approved the Amended and Restated 2024 Equity Incentive Plan at the Annual Meeting on June 3, 2026. The plan includes a significant increase in shares reserved for issuance and an amendment to its annual evergreen provision. Additionally, stockholders elected three Class II directors and ratified KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
Key Highlights
- Stockholders approved the Amended and Restated 2024 Equity Incentive Plan with 16,431,575 votes For.
- The plan includes a one-time increase of 3,231,638 shares (approx. 8% of outstanding shares) reserved for issuance.
- The annual "evergreen" provision was amended to remove the 2,407,100 share limit, maintaining a 5% annual increase.
- R. Michael Carruthers, Valerie M. Jansen, M.D., Ph.D., and Edward T. Mathers were elected as Class II directors.
- KPMG LLP was ratified as the independent registered public accounting firm for fiscal year 2026 with 25,329,425 votes For.
Price Impact
More from OKUR